Abstract 573P
Background
Tumour infiltrating CD8+ cytotoxic T cells confer favourable prognosis in colorectal cancer (CRC). The added prognostic value of other immune cells is unclear.
Methods
We used multiparameter co-immunofluorescence to determine the density of CD8+, CD20+, FoxP3+ and CD68+ cells in the intraepithelial (IE) and intrastromal (IS) compartments in stage II/III CRCs from the SCOT and QUASAR2 trials. We determined marker prognostic and predictive value by Cox regression of SCOT cases, with validation in the QUASAR2 cohort.
Results
Our study included 2,340 SCOT and 1,069 QUASAR2 cases. Univariable analysis of recurrence-free interval (RFI) in SCOT revealed expected prognostic value of intraepithelial CD8 (CD8IE) (continuous variable: HR for cases at 75th vs 25th percentile (HR75vs25)= 0.73, 95% CI=0.68-0.79, P=2.5e-16) and, less expectedly FoxP3 within tumour stroma (FoxP3IS) (HR75vs25)= 0.71, 95% CI=0.64-0.78, P=1.5e-13), but not epithelium. CD8IE and FoxP3IS were independently prognostic in multivariable analysis, and a composite marker including both (CD8IE-Foxp3IS) was superior to either alone as a continuous variable (adjHR75vs25= 0.70; 95%CI=0.63–0.78; P=5.1e-11), and when categorised into three groups (Low/Int/High) using sample medians (Int vs High HR = 1.60, 95%CI=1.24–2.05, P=2.5e-04; Low vs High HR = 2.30, 95%CI=1.80–2.95; P=3.6e-11). These results were validated in the QUASAR2 trial. Pooled analysis of both studies revealed interactions between CD8IE-FoxP3IS and tumour sidedness (adjP INT=0.010), stromal proportion (adjP INT=0.018), and MMR status (adjP INT=0.079). CD8IE-FoxP3IS refined stage III risk groups, with clinical low risk (T1-3, N1), CD8IE-FoxP3IS low cases demonstrating similar 3-year recurrence-free probability to clinical high risk (T4 and/or N2), CD8IE-FoxP3IS high cases (79.2 vs 76.4%, adj log-rank P=0.16).
Conclusions
Combined evaluation of CD8IE and FoxP3IS is superior to single markers and refines CRC risk stratification. FoxP3IS prognostic value is inconsistent with an immunosuppressive role; further investigation of these cells as an immunotherapy target is merited.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D.N. Church.
Funding
Cancer Research UK, National Institutes for Health Research, Promedica Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
548P - Diffuse midline gliomas H3K27-altered in adults, the experience of an oncology center
Presenter: Carolina Trabulo
Session: Poster session 10
561P - Risk of colorectal cancer and premalignant lesions after kidney transplantation
Presenter: Koen Zwart
Session: Poster session 10
562P - Quantifying the effect of colonoscopy and polypectomy rates in stage shift of colorectal cancer and reduced need for adjuvant chemotherapy
Presenter: Mina Sarofim
Session: Poster session 10
563P - The impact of participation in colorectal cancer screening: A population-based results from Lithuania
Presenter: Tomas Poskus
Session: Poster session 10
564P - A large-scale real-world study for colorectal cancer screening
Presenter: Song LIU
Session: Poster session 10
565P - Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
Presenter: Doreen Gisder
Session: Poster session 10
566P - Long-term survivorship outcomes of adolescents and young adults (AYA) with cancer of the lower gastrointestinal tract
Presenter: Winette Van Der Graaf
Session: Poster session 10
567P - Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
Presenter: Elisabeth Bergen
Session: Poster session 10
568P - Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial
Presenter: Faiz Jabbar
Session: Poster session 10
569P - Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
Presenter: Frank Sinicrope
Session: Poster session 10